PROTEINS WITH A DOUBLE FUNCTION AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM Russian patent published in 2021 - IPC C07K14/46 C07K14/50 C07K14/605 C07K19/00 A61K38/17 A61K38/18 A61K38/26 C12P21/02 A61P1/16 A61P3/04 A61P3/06 A61P3/10 

FIELD: biotechnology.

SUBSTANCE: invention relates to fused proteins with a double function based on fibroblast growth factor 21 (FGF21), and can be used in medicine for treating FGF21-associated disorders. Fused protein contains a mutant FGF21, an immunoglobulin Fc region and a biologically active protein, which is glucagon-like peptide-1 (GLP-1) or its mutant. In the fusion protein structure, the FGF21 mutant protein is bound to the immunoglobulin Fc region through a linker, where the linker is a peptide consisting of 10–30 amino acid residues, where the linker is connected to the C-terminus of the immunoglobulin Fc region and the N-terminal end of the mutant protein FGF21. Fused protein comprises a biologically active protein, an immunoglobulin Fc region and a mutant FGF21 protein sequentially bound to the N-terminus to the C-terminus. Also disclosed are a nucleic acid, an expression vector and a host cell for producing said fused protein by a recombinant method.

EFFECT: invention enables to obtain FGF21 and GLP-1-based fusion protein with improved in vivo pot life, stability and pharmacological efficacy.

16 cl, 10 tbl, 11 ex, 21 dwg